Pancreatic cancer is one of the most malignant tumors. It is called “the king of cancer” because of its low survival rate and extremely short survival period. It is usually asymptomatic in the early stage and often spreads to the whole body when it is diagnosed. Pancreatic cancer is… Continue Reading Nature: The king of cancer also has weakness

  On November 21, Taiwan’s OBI Pharma announced that the FDA has granted OBI-888 the right to treat orphan drugs for pancreatic cancer. OBI-888 is a first-in-class passive immunotherapy treatment of monoclonal antibody against Globo H, a tumor cell surface antigen, whose mechanism of action is antibody-dependent cytotoxicity, antibody-dependent macrophage… Continue Reading Taiwan’s Hao Ding Harvest FDA’s third orphan drug qualification: OBI-888 for the treatment of pancreatic cancer